Cardiotoxicity Clinical Trial
Official title:
Randomized Controlled Trial on Comprehensive Exercise-based Cardiac Rehabilitation Programs for the Prevention of Anthracyclines and/or Anti-HER2 Antibodies-induced Cardiotoxicity in Breast Cancer
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in women with breast cancer. Participants will be randomly allocated to cardiac rehabilitation (intervention group) or conventional management with physical exercise recommendation (control group).
Cardiovascular toxicity caused by chemotherapy is the leading cause of death in patients who survive cancer. Physical exercise during chemotherapy has shown to improve quality of life and decrease the risk of death. The objective of this project is to determine whether an intervention through a comprehensive cardiac rehabilitation program including supervised physical exercise is able to prevent anthracyclines and / or anti-HER-2 antibodies-induced cardiotoxicity in women with breast cancer. For this purpose, the investigators intend to conduct a randomized controlled study including female patients managed under the same cardiotoxicity prevention protocol (clinical, laboratory and echocardiographic follow-up assessment). Patients will be randomized to a non-pharmacological intervention (participation in a multidisciplinary cardiac rehabilitation program with supervised exercise training) or control (conventional management and physical activity recommendation)*. The investigators hypothesize that a cardiac rehabilitation program may limit chemotherapy-induced cardiotoxicity in women with breast cancer, improve cardiac remodeling assessed by echocardiography and enhance their global cardiovascular risk profile to a greater extent, compared to control group. * OF NOTE: Due to the COVID-19 pandemics, several modifications to the original protocol were introduced for safety reasons or motivated by the health situation, namely: 1. Intervention: Change from centre-based to telematic supervised exercise training sessions provided within the cardiac rehabilitation program (intervention group) 2. Secondary outcome 4: Change in functional capacity assessed by conventional ergometry or cardiopulmonary exercise test OR the 6-minute walking test (metabolic equivalents: METs or peak oxygen consumption: VO2) 3. Recruiting centres: One centre (Hospital Universitari Vall d'Hebron) withdrew from the study due to the impossibility of assuming its execution. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05271162 -
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
|
Phase 3 | |
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Recruiting |
NCT04790266 -
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
|
||
Enrolling by invitation |
NCT04305613 -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
|
||
Not yet recruiting |
NCT05040867 -
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT05851053 -
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
|
||
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Enrolling by invitation |
NCT04877899 -
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
|
||
Recruiting |
NCT05096338 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
|
||
Recruiting |
NCT05078190 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
|
||
Recruiting |
NCT04632407 -
Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?
|
N/A | |
Completed |
NCT00543062 -
Staccato Prochlorperazine Thorough QT/QTc
|
Phase 1 | |
Recruiting |
NCT05159479 -
Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
|
||
Not yet recruiting |
NCT06005259 -
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
|
Phase 4 | |
Recruiting |
NCT05406635 -
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT04047901 -
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
|
N/A | |
Terminated |
NCT03038997 -
Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
|
||
Completed |
NCT01246778 -
Sunitinib and Atrial Trabeculae Contractility
|
N/A |